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Abstract 
Background: XMU-MP-1 is an inhibitor of the Hippo pathway kinases MST1/2 and has been shown to promote the 
downstream activation of the pro-proliferative, pro-regenerative and anti-apoptotic transcriptional regulator YAP1. 
We tested whether XMU-MP-1 can activate YAP1 in a model human mini-organ, namely the hair follicle, to determine 
whether it can be pharmacologically exploited to promote regeneration in the hair follicle as a novel strategy to treat 
pathological hair loss disorders.
Results: XMU-MP-1 treatment inhibited MOB1 phosphorylation but did not increase active YAP1 in the hair follicle. 
Rather than promote proliferation, XMU-MP-1 serendipitously decreased the number of Ki-67+, EdU+ and phospho 
histone H3+ hair matrix keratinocytes and antagonised the cytotoxic effects of paclitaxel.
Conclusions: XMU-MP-1 perturbs epithelial cell cycle progression in a model human mini-organ. This may arise as 
an off-target effect, especially when XMU-MP-1 has been described to strongly inhibit 21 additional kinases beyond 
MST1/2. Therefore, whilst these effects may be dependent on tissue context, researchers should exercise caution 
when interpreting the effects of XMU-MP-1, especially in tissues with actively proliferating cell populations.
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Background
Hair loss can be highly distressing for affected individu-
als, and efficacious prevention and treatment options 
are limited. Therefore, there is an urgent need to iden-
tify new therapeutic approaches that either protect the 
hair follicle from damage or promote regeneration in the 
context of potentially permanent hair loss disorders asso-
ciated with cancer treatments and inflammatory condi-
tions [1–3].
The Hippo pathway, as a key regulator of growth and 
differentiation, has emerged as an attractive target in 
translational medicine to promote tissue repair and 
regeneration [4–6]. The Hippo pathway is a kinase cas-
cade, whereby the MST1/2 kinases activate the LATS1/2 
kinases, which in turn phosphorylate and inactivate the 
transcriptional regulator YAP1 [7]. YAP1 is pro-regener-
ative and anti-apoptotic, and its inactivation via Hippo 
signalling prevents the transcription of genes associated 
with proliferation and survival [7].
Previous work has identified the small molecule XMU-
MP-1 as a potent inhibitor of MST1/2. Accordingly, it 
has been reported that XMU-MP-1 increases YAP1 acti-
vation and decreases apoptosis, which promotes repair 
and protection against damage in models of liver injury 
and experimentally-induced colitis [8]. However, sup-
porting KINOMEscan profiling data within this same 
study reported that XMU-MP-1 has a strong affinity to 
inhibit an additional 21 kinases [8]. Despite this, follow-
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XMU-MP-1 to specifically target Hippo signalling, high-
lighting protective applications against early brain injury 
[9] and cardiac pressure overload [10].
As such, we sought to determine whether XMU-MP-1, 
through its putative growth promoting properties, could 
be exploited to protect against damage and promote 
regeneration in the hair follicle as a novel means to thera-
peutically manage pathological hair loss disorders. Using 
an ex vivo human hair follicle mini-organ culture model 
[11], we treated terminal human anagen VI hair follicles 
with XMU-MP-1. Anagen is the active growth phase 
of the hair cycle, whereby hair follicles show extensive 
keratinocyte proliferation and differentiation to support 
hair shaft production which can last for years [12]. To 
dissect the potential growth promoting effects of phar-
macological Hippo pathway inactivation, we analysed 
cell cycle parameters in proliferating human hair follicle 
matrix keratinocytes using in  situ methods previously 
established and routinely utilised in human hair research 
[13].
Results
XMU‑MP‑1 perturbs cell cycle progression in proliferating 
human hair matrix keratinocytes
To first determine if XMU-MP-1 augments prolifera-
tion in the human hair follicle, we treated hair follicles 
in ex  vivo organ culture [11] with 3  µM XMU-MP-1 
for 24  h and systematically dissected the cell cycle 
effects on anagen VI hair matrix keratinocytes [12, 
13]. We found that the total number of Ki-67+ hair 
matrix keratinocytes was decreased in treated follicles 
(Fig.  1a, d), suggesting that XMU-MP-1 perturbs the 
Fig. 1 XMU-MP-1 perturbs cell cycle progression in proliferating human hair matrix keratinocytes. a Treatment of human hair follicles with 
3 µM XMU-MP-1 for 24 h significantly decreases the number of Ki-67 + cells in the hair matrix, whilst simultaneously increasing Ki-67 protein 
expression (p = 0.0002 for both analyses). Mann–Whitney test performed on 7–9 hair follicles from 3 donors. b XMU-MP-1 significantly (p =0.0107) 
decreases the number EdU + cells (S-phase). Unpaired t-test performed on 10 hair follicles per group from 3 donors. c XMU-MP-1 significantly 
(p ≤ 0.0001) decreases the number of mitotic phospho histone H3 (pH3) + cells. Mann–Whitney test performed on 7–9 hair follicles from 3 
donors. d Immunofluorescence images show that XMU-MP-1 perturbs markers of cell cycle progression in the human hair matrix. 50 µm scale. 
e XMU-MP-1 does not affect the immunoreactivity of active YAP1 in the proliferative hair matrix but significantly (p =0.028) decreases active 
YAP1 immunoreactivity in the hair follicle pre-cortex. Mann–Whitney test performed on 7-8 hair follicles from 3 donors. f XMU-MP-1 significantly 
(p ≤ 0.0001) decreases phospho-MOB1 (Thr35) immunoreactivity in the hair follicle matrix and pre-cortex. Unpaired t-test performed on 9–10 hair 
follicles from 3 donors. g Immunofluorescence images show that XMU-MP-1 selectively decreases active YAP1 immunoreactivity in the hair follicle 
pre-cortex and decreases phospho-MOB1 (Thr35) immunoreactivity in the hair follicle matrix and pre-cortex. Error bars represent standard error. FI 
Fluorescence intensity, HM Hair Matrix
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cell cycle. Conversely, this coincided with an increase 
in the intensity of Ki-67 immunoreactivity in the hair 
matrix (Fig.  1a, d), indicating increased Ki-67 protein 
expression within the reduced fraction of proliferating 
cells. The number of cells in S-phase (EdU+) (Fig. 1b, 
d) and the number of mitotic phospho histone H3 
(pH3)+ cells in the hair matrix was also significantly 
decreased (Fig. 1c, d). Together these results show that 
XMU-MP-1 disrupts normal cell cycle progression in a 
highly proliferative model human tissue system.
XMU‑MP‑1 does not significantly increase active YAP1 
in the human hair follicle matrix
We next explored the effects of XMU-MP-1 treat-
ment on Hippo pathway proteins downstream of 
MST1/2. Active YAP1 is abundantly expressed in the 
human hair follicle, indicating functional importance 
to hair growth (Fig.  1e, g). XMU-MP-1 treatment did 
not significantly affect the level of active YAP1 stain-
ing in proliferating hair matrix keratinocytes (Fig.  1e, 
g). However, active YAP1 staining was selectively 
decreased in cell cycle-arrested terminally differen-
tiating keratinocytes of the pre-cortex and hair shaft 
(Fig.  1e, g) [12]. This indicates that XMU-MP-1 does 
not effectively enhance active YAP1 in the hair follicle 
and may even disrupt active YAP1 in differentiating 
keratinocytes.
Next, we looked at phospho-MOB1 (Thr35) staining. 
In the Hippo-YAP pathway, LATS1/2–MOB1 is phos-
phorylated and activated by MST1/2-SAV1, which in 
turn inactivates YAP1 [7]. XMU-MP-1 treatment sig-
nificantly decreased phospho-MOB1 staining in the 
hair matrix (Fig. 1f, g), which is in accordance with the 
successful inhibition of MST1/2. However, this did not 
result in a concomitant increase in active YAP1 staining 
or proliferation.
XMU‑MP‑1 antagonises cell cycle‑dependent paclitaxel 
cytotoxicity
To further probe the cell cycle-antagonising effects of 
XMU-MP-1, we co-cultured human hair follicles with 
XMU-MP-1 and the chemotherapy agent paclitaxel. 
We found that XMU-MP-1 blocked the cell cycle-
dependent cytotoxic effects of paclitaxel, whereby the 
accumulation of pH3+ and cleaved caspase 3+ cells 
[2] was prevented (Fig.  2a, b). Moreover, XMU-MP-1 
prevented a paclitaxel-induced nascent transcription 
block in abnormally dividing hair matrix keratinocytes 
(Fig. 2c) [2, 14]. This further supports that XMU-MP-1 
can antagonise cell cycle progression in human hair 
matrix keratinocytes.
Aurora B kinase inhibition blocks the paclitaxel‑induced 
accumulation of phospho histone H3+ cells in the hair 
matrix
As it has previously been shown that XMU-MP-1 
strongly inhibits 21 kinases beyond MST1/2, including 
TAO Kinases 1/2/3, JAK1, Aurora A/B and MEKK2/3 
[8], we reasoned that the cell cycle arrest promoted by 
XMU-MP-1 in the hair follicle could be attributed to the 
off-target inhibition of kinases functionally important to 
cell growth.
The Aurora A/B kinases are critical mitotic regula-
tors that phosphorylate histone H3, and the inhibition of 
these kinases can induce growth arrest [15–19]. When 
we independently tested the effects of Aurora B inhibi-
tion in the hair follicle for 24 h using 100 nM AZD1152 
(Barasertib), we found that it blocked accumulation of 
pH3+ cells in the hair matrix following paclitaxel treat-
ment (Fig. 2d, e). However, AZD1152 co-treatment only 
resulted in a trending decrease in the number of cleaved 
caspase 3+ cells relative to paclitaxel-only treated hair 
follicles (Fig.  2d, e), possibly due to the independent 
apoptosis-promoting effects of AZD1152 [16]. Whilst 
no direct causative connection can be made between the 
observed effects of XMU-MP-1 and AZD1152 in the hair 
follicle, these data highlight a potential mechanism for 
XMU-MP-1 that may be capable of impairing normal cell 
cycle progression.
Discussion
In this study we show that, despite decreasing MOB1 
phosphorylation, XMU-MP-1 does not significantly 
increase active YAP1 immunoreactivity or promote pro-
liferation in the human hair follicle. Instead, XMU-MP-1 
inhibited proliferation, which was subsequently capable 
of antagonising cell cycle-dependent chemotherapy-
induced damage.
Given that XMU-MP-1 has been described to activate 
YAP1 via the specific inhibition of MST1/2 [8], we were 
initially surprised to find that XMU-MP-1 reduced the 
number of cycling Ki-67+ cells in the hair follicle matrix. 
Follow-up analyses further revealed that XMU-MP-1 
significantly decreased the number of cells progress-
ing through S-phase (EdU+) and decreased the number 
of pH3+ cells, suggesting that progression to M-phase 
and/or the mitotic phosphorylation of histone H3 was 
impaired.
To explore this further, we tested how hair follicles 
treated with paclitaxel responded to co-treatment with 
XMU-MP-1. Paclitaxel, which causes chemotherapy 
induced-alopecia, induces extensive mitotic defects and 
apoptosis in the hair matrix [2]. We found that XMU-
MP-1 blocked cell cycle-dependent paclitaxel cytotoxicity 
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in the hair follicle, as achieved previously via targeted G1 
arrest using the CDK4/6 inhibitor palbociclib [2]. This 
data further supports that XMU-MP-1 can promote 
cell cycle arrest. Interestingly, XMU-MP-1 was effective 
against paclitaxel in the human hair follicle without the 
need for pre-treatment, as is required when targeting 
CDK4/6 [2]. This indicates that XMU-MP-1 might rap-
idly disrupt cell cycle progression into M-phase, where 
cells in the hair follicle are most vulnerable to taxanes [2].
Fan et  al. describe, via their supporting KINOMEs-
can data, that XMU-MP-1 strongly inhibits numerous 
kinases beyond MST1/2 [8]. We therefore speculated 
that this lack of selectivity could account for the obser-
vations described in our study. In particular, we noted 
that XMU-MP-1 exhibits high-affinity binding with the 
Aurora A/B kinases, which control mitosis [17] and phos-
phorylate histone H3 [15]. It is therefore plausible that 
the effects exerted by XMU-MP-1 on the human hair fol-
licle could be attributed to Aurora A/B kinase inhibition, 
especially when pharmacological Aurora kinase inhibi-
tion arrests growth [18, 19]. Indeed, we found that the 
independent treatment of human hair follicles with the 
Aurora B inhibitor AZD1152 also antagonised the cell 
cycle-dependent effects of paclitaxel in the hair follicle.
It should be noted that this experimentally replicated 
phenotype does not provide a causative connection 
between the effects of XMU-MP-1 treatment and tar-
geted Aurora B kinase inhibition, especially when XMU-
MP-1 could target numerous additional kinases that may 
influence the cell cycle. Therefore, whilst we can con-
clude that XMU-MP-1 perturbs cell cycle progression in 
the human hair follicle, the exact mechanism(s) by which 
this is exerted remains inconclusive.
In addition, we were unable to determine where exactly 
hair matrix keratinocytes are arrested in the cell cycle by 
XMU-MP-1 or AZD1152. Probing the cell cycle through 
in  situ analyses is the preferred approach in human 
hair research [13]. This permits the study of hair matrix 
keratinocytes with respect to their spatial tissue con-
text, and avoids the caveats associated with methods that 
require tissue disruption and analysis of cells outside 
of their native habitat [13]. However, in the absence of 
adequate multiplexing, analysis of cell cycle parameters 
in  situ limits our ability to accurately quantify the cell 
Fig. 2 XMU-MP-1 antagonises cell cycle-dependent paclitaxel cytotoxicity. a, b XMU-MP-1 blocks the accumulation of phospho histone H3 
(pH3)+ and cleaved caspase 3+ (CC3) cells in the hair matrix seen following paclitaxel treatment [2]. 50 µm scale. Analysis conducted using 4-7 hair 
follicles per condition from 2 donors. c Paclitaxel blocks nascent RNA synthesis, as visualised by 5-ethynyl uridine (EU) incorporation, in abnormally 
dividing hair matrix keratinocytes (white arrows) [2, 14]. This paclitaxel-induced block in RNA synthesis is prevented by XMU-MP-1 treatment. d, e 
Treatment with the Aurora B inhibitor AZD1152 also blocks the accumulation of pH3 + cells in the hair matrix following paclitaxel treatment, but 
results only in a trending reduction in the number of cleaved caspase 3 + cells, possibly due to the independent cytotoxicity of AZD1152 [16]. 
Analysis conducted using 4–5 hair follicles per condition from 1 donor. Adjusted p values = 0.0006 [***] and < 0.0001 [****]. Ordinary one-way 
ANOVA with multiple comparisons performed
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cycle-phase distribution of a given population of cells. 
Future work would therefore benefit from the devel-
opment and optimisation of imaging mass cytometry-
based approaches to multiplex cell cycle-related readout 
parameters [20], which would allow researchers study-
ing the human hair follicle to better analyse the cell cycle 
phase distribution of hair matrix keratocytes without 
sacrificing localisation data.
Conclusions
XMU-MP-1 treatment did not significantly increase 
active YAP1 in a model human mini-organ; instead, it 
promoted epithelial cell cycle arrest which was capable of 
antagonising the cytotoxic paclitaxel. This may be due to 
the off-target inhibition of other functionally important 
kinases beyond MST1/2. Researchers should therefore 
exercise caution when utilising XMU-MP-1, especially 
when studying proliferative tissue systems. Further-
more, despite these unanticipated research outcomes, 
this work serendipitously identifies XMU-MP-1 as a fast-
acting candidate small molecule that could be clinically 
exploited to antagonise cell cycle-dependent chemother-
apy-induced damage.
Methods
Human hair follicle organ culture
Human scalp tissue was obtained with informed con-
sent and stored in accordance with Human Tissue Act 
regulations.
Scalp tissue was dissected to isolate full length ana-
gen VI hair follicles [11]. Hair follicles were cultured in 
24 well plates, at 37  °C in 5%  CO2/95% air, in hair folli-
cle medium (500  µl per well) comprised of: Williams E 
medium supplemented with 10 µg/ml insulin, 100 U/ml 
penicillin, 100  μg/ml streptomycin, 2  mM  l-glutamine 
and 10  ng/ml hydrocortisone. Hair follicles were incu-
bated for 24 h in the presence of either vehicle (DMSO 
max. < 0.05%), 3 μM XMU-MP-1 (#S8334, Selleckchem), 
100  nM AZD1152-HQPA (#ab142049, Abcam) and 
100 nM paclitaxel (#1097, Tocris) with treatments deliv-
ered in combination where indicated. Where required, 
hair follicles were treated with either 20  μM 5-Ethynyl-
2′-deoxyuridine (EdU) or 0.5  mM 5‐Ethynyl Uridine 
(EU), for 4 h and 2 h respectively, prior to completion of 
hair follicle organ culture experiments. Upon comple-
tion of experiments, hair follicles were frozen in embed-
ding medium using liquid nitrogen and cryosectioned at 
10 µm. Slides were stored temporarily at − 20 °C.
Immunofluorescence
Slides with comparable tissue sections of the human hair 
matrix were selected for staining and allowed to air dry at 
room temperature for 10  min. Slides were subsequently 
fixed in ice-cold acetone for 10  min and left to air dry 
for a further 10  min. Each section was circumscribed 
using a hydrophobic barrier PAP pen (#H4000 Vector 
Laboratories).
Incorporated EdU/EU was detected as per kit instruc-
tions (Click‐iT™ EdU Alexa Fluor™ 594 Imaging Kit, 
#C10339, Thermo Fisher Scientific; Click‐iT™ RNA 
Alexa Fluor™ 594 Imaging Kit, #C10330, Thermo Fisher 
Scientific).
Primary antibodies were diluted in PBS (see below) 
and were applied to sections; slides were then incubated 
at 4 °C overnight. Slides were then washed three times in 
PBS for 2  min and secondary fluorescent antibody was 
applied at 1:200 in PBS for 45 min at room temperature 
(anti-mouse/rabbit Alexa Fluor 488/594). Slides were 
then washed three times in PBS for 2  min and treated 
with Hoechst 33342 (1:1000 in PBS) (#H3570, Thermo 
Fisher Scientific). Slides were finally washed in PBS for 
2  min and mounted using aqueous mounting medium 
(#S3025, Dako).
Antibodies
Anti‐Ki‐67 [SP6] (Abcam, ab16667) (1:50). Phospho-
Histone H3 S10 (pH3) (#9706S, Cell Signaling Technol-
ogy) (1:100). Cleaved Caspase-3 (#9661, Cell Signaling 
Technology) (1:50). Phospho-MOB1 (Thr35) (D2F10) 
(#8699, Cell Signaling Technology) (1:100). Anti-YAP1 
antibody [EPR19812] (active, non-phosphorylated form) 
(ab205270, Abcam) (1:50). Alexa Fluor 488 and 594 
secondary fluorescent antibodies (#A11005, #A11008, 
#A11037, Thermo Fisher Scientific) (1:200).
Microscopy and analysis
Microscopy and imaging was performed using a BZ‐8000 
fluorescence microscope (Keyence). Images were han-
dled using ImageJ (NIH) and quantitative data was han-
dled using GraphPad Prism 8 (GraphPad Software).
Fluorescence intensity and positive cell number was 
measured within the hair matrix between treatment con-
ditions. Statistical testing employed Unpaired t test or the 
Mann–Whitney U test. D’Agostino & Pearson omnibus 
test was used to assess normality. For multiple treatment 
groups, Ordinary one-way ANOVA with multiple com-
parisons was performed.
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